IP Library Granted Patent US 7,893,299
Granted Patent B2
US 7,893,299 · App. 11/487,018 · Granted Feb 22, 2011

Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators

Assignees: Nereus Pharmaceuticals, Inc.; The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,893,299
App. No.
11/487,018
Granted
Feb 22, 2011
Kind
B2
Abstract

Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection.

Claims (16)

1. A compound having the following chemical structure:

wherein:

R 2 is selected from the group consisting of hydrogen, a halogen, COOH, C 1 -C 12 carboxylic acids, C 1 -C 12 acyl halides, C 1 -C 12 acyl residues, C 1 -C 12 esters, C 1 -C 12 secondary amides, (C 1 -C 12 )(C 1 -C 12 ) tertiary amides, (C 1 -C 12 ) cyclic amides, (C 1 -C 12 ) amines, C 1 -C 12 alcohols, (C 1-C 12 )(C 1 -C 12 ) ethers, C 1 -C 12 alkyls, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyls, C 2 -C 12 substituted alkenyls, and C 5 -C 12 aryls;

R 17 is selected from C 5 -C 12 cyclic alkyls; C 5 -C 12 cyclic alkenyls; C 5 -C 12 substituted cyclic alkyls; C 5 -C 12 substituted cyclic alkenyls; phenyl and C 5 -C 12 aryls;

R 9 is selected from hydrogen, a halogen, C 1 -C 12 alkyl, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyl, C 2 -C 12 substituted alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alcohol, C 1 -C 12 acyl, and C 5 -C 12 aryl;

R 3 -R 5 , R 7 , R 8 , and R 11 -R 13 are each separately selected from hydrogen, a halogen, C 1 -C 12 alkyl, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyl, C 2 -C 12 substituted alkenyl, C 2 -C 12 alkynyl, and C 5 -C 12 aryl;

R 6 is selected from hydrogen, a halogen, C 1 -C 12 alkyl, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyl, C 2 -C 12 substituted alkenyl, and C 2 -C 12 alkynyl;

R 10 is selected from hydrogen, a halogen, CH 2 , C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, C 2 -C 6 alkenyl, C 2 -C 6 substituted alkenyl, C 1 -C 12 alcohol, and C 5 -C 12 aryl;

R 14 and R 15 are separately selected from hydrogen, a halogen, CH 2 , C 1 -C 6 alkyl, C 1 -C 6 substituted alkyl, C 2 -C 6 alkenyl, C 2 -C 6 substituted alkenyl, C 1 -C 6 alcohol, and C 5 -C 6 aryl; and

R 16 is selected from the group consisting of hydrogen, a halogen, COOH, C 1 -C 12 carboxylic acids, C 1 -C 12 acyl halides, C 1 -C 12 acyl residues, C 1 -C 12 esters, C 1 -C 12 secondary amides, (C 1 -C 12 )(C 1 -C 12 ) tertiary amides, (C 1 -C 12 ) cyclic amides, (C 1 -C 12 ) amines, C 1 -C 12 alcohols, (C 1 -C 12 )(C 1 -C 12 ) ethers, C 1 -C 12 alkyls, C 1 -C 12 substituted alkyls, C 2 -C 12 alkenyls, C 2 -C 12 substituted alkenyls, and C 5 -C 12 aryls;

wherein the compound includes the acid-addition salts of the above compounds.

2. The compound of claim 1 wherein R 16 is hydrogen.

3. The compound of claim 1 wherein R 17 is cyclohexane; R 16 is hydrogen; and R 3 -R 5 , R 7 , R 8 , R 11 -R 15 is each hydrogen.

4. The compound of claim 1 , wherein R 16 and R 17 form a 3 to 12 membered ring.

5. A compound:

and acid-addition salts thereof.

Assignments (4)
SECURITY AGREEMENT Recorded May 21, 2009
From: NEREUS PHARMACEUTICALS, INC.
To: HBM BIOVENTURES (CAYMAN) LTD.; HBM BIOCAPITAL (EUR) L.P.; HBM BIOCAPITAL (USD) L.P.; PRIVATE LIFE BIOMED AG; ALSTERTOR PRIVATE LIFE GMBH & CO. KG; ADVENT HEALTHCARE AND LIFE SCIENCES III LIMITED PARTNERSHIP; ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP; ADVENT PARTNERS HLS III LIMITED PARTNERSHIP; PACIFIC VENTURE GROUP II, L.P.; PVG ASSOCIATES II, L.P.; FORWARD VENTURES IV, L.P.; FORWARD VENTURES IV B, L.P.; GIMV N.V.; GIMV ADVIESBEHEER LIFE SCIENCES N.V.; LOTUS BIOSCIENCE INVESTMENT HOLDS LTD; NOVARTIS BIOVENTURE FUND / NOVARTIS INTERNATIONAL AIG; HENSLER, MARY; JACOBS, ROBERT; WS INVESTMENT COMPANY; GENAVENT PARTNERS LP; ASTELLAS VENTURE FUND I LP; ROCHE FINANCE LTD; ALTA CALIFORNIA PARTNERS II, L.P.; ALTA EMBARCADERO PARTNERS II, LLC; ALTA CALIFORNIA PARTNERS II, L.P. - NEW POOL
Reel/Frame 022719/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2008
From: THEODORAKIS, EMMANUEL A.
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA,THE
Reel/Frame 020715/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2008
From: PALLADINO, MICHAEL A.; MACHERIA, VENKAT RAMI REDDY; CHAO, TA-HSIANG; SUH, YOUNG-GER
To: NEREUS PHARMACEUTICALS, INC.
Reel/Frame 020725/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2006
From: KINTZLEY, TOM G.; HELKEY, JOHN; HOLTE, IVAN; JOHNSON, LEE ROY; MILLER, TODD R.
To: HEXION SPECIALTY CHEMICALS, INC.
Reel/Frame 018379/0576 →
Continuity (6)
Provisional Application 60701932 · Jul 21, 2005
Provisional Application 60734590 · Nov 7, 2005
Provisional Application 60734679 · Nov 7, 2005
Provisional Application 60749542 · Dec 12, 2005
Provisional Application 60785223 · Mar 22, 2006
Related Publication 20080064753A1 · Mar 13, 2008